Topics Companies

 
News Articles for Topics Companies top ^
2014/4/3
Product has fast track designation by FDA Potential to be the first topical treatment approved for painful diabetic neuropathy RALEIGH, N.C. , April 3, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.
Sign-up for BioDelivery Sciences Announces Enrollment of the First Patient in a Phase 3 Clinical Study of Clonidine Topical Gel for Painful Diabetic Neuropathy investment picks
Phase 3 to begin first quarter 2014; Fast track designation confirmed for NDA program RALEIGH, N.C. , Dec.
Sign-up for Positive FDA Meeting Confirms BDSI Phase 3 Program for Clonidine Topical Gel for Treatment of Painful Diabetic Neuropathy investment picks
2014/1/21
- Novel thrombin-based topical hemostat controls bleeding from vascular access sites - Designed specifically for use around indwelling lines up to 12F - Contains antimicrobial properties of silver chloride MINNEAPOLIS, Jan.
Sign-up for Vascular Solutions Launches ThrombiDisc(TM) Topical Hemostat in U.S. investment picks
2013/9/12
PLEASANTON, Calif., Sept.
Sign-up for Adept Announces Tech Topics Webinar Series investment picks
By Nicole Lundeen VIENNA--A possible capital increase isn't a topic on the agenda at the moment for Telekom Austria AG (TKAGY), Chief Executive Officer Hannes Ametsreiter said Friday.
Sign-up for Telekom Austria CEO: A Capital Increase is Not a Topic at the Moment investment picks
Cottonelle Brand Teams Up with Documentary Filmmaker to Get People Talking… About their Bums DALLAS , Aug.
Sign-up for Poll Finds America is Ready to Talk Taboo Topics -- Well-Known Toilet Paper Brand Sets Out to Start this Conversation investment picks
Pharmaceutical formulation development and manufacturing services provider Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq:CBRX) has been selected as the formulation development partner for a major pan-European collaborative project.
Sign-up for Molecular Profiles Selected to Develop Topical & Oral Psoriasis Products for Telormedix investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1075889&ProfileId=051205&sourceType=1 CARSON CITY, NV --
Sign-up for Rapid Fire Marketing Updates Shareholders on Multiple Topics investment picks
2014/1/8
Studies designed to compare performance of Androxal to testosterone (T) replacement in restoring and maintaining normal testicular function Anticipated to expand Androxal label and thereby increase commercial potential Identical studies to be conducted at 23 US clinical sites Topline results expected by October 2014 Study completion not expected to affect filing date for the NDA in Q4 2014 THE WOODLANDS, Texas, Jan.
Sign-up for Repros Initiates Two Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel investment picks
2014/1/13
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1081275&ProfileId=051205&sourceType=1 LOS ANGELES, CA --
Sign-up for Medical Greens (SKTO) Announces New Topical Medical Cannabis Product Line Topikoil(TM) investment picks
2014/1/23
Financial services experts to discuss key regulatory issues and developments for internal audit and compliance professionals MENLO PARK, Calif.
Sign-up for Protiviti Webinar: Regulatory Hot Topics for Financial Services in 2014 investment picks
2014/2/12
REDWOOD CITY, Calif., Feb.
Sign-up for Managing Big-Data Challenges in Legal Matters is Topic of UBIC's Feb. 19 Webinar investment picks
2014/2/24
NCM Media Networks, the largest national cinema network in the U.S., is partnering with Twitter Amplify to develop a new branded entertainment series that will bring the most exciting movie conversations, Tweets and Vines to the big screen.
Sign-up for NCM Media Networks Bring Trending Movie Topics to the Big Screen in New Weekly Show With Twitter investment picks
2014/3/7
PHOENIX , March 7, 2014 /PRNewswire-USNewswire/ -- Not only are neuropathic pain symptoms quite common in knee osteoarthritis (OA), but scientists can predict who will respond to treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) by assessing the nervous system's own capacity to regulate pain, new research suggests.
Sign-up for Higher Functioning Endogenous Opioid System Predicts Better Treatment Response For Neuropathic Pain Treated With Topical NSAIDs: Study investment picks
2014/4/14
Company expects topline results by October 2014 Studies designed to compare performance of Androxal to testosterone replacement in restoring and maintaining normal testicular function Both identical studies to be conducted at 22 US clinical sites Timing of study completion expected to allow for submission with the planned filing of NDA in Q4 2014 THE WOODLANDS, Texas, April 14, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today announced it has reached the enrollment goal of 120 subjects in the first of two previously announced head-to-head studies comparing Androxal to the leading US testosterone replacement therapy.
Sign-up for Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Topics Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Top-Ranked Research  |  Next: Topline Results